Citing a lack of data and failure to conduct category 2 and 3 tests on abuse deterrent properties, two FDA advisory committees voted 22-1 Wednesday against recommending approval of Intellipharmaceutics International Inc.'s IPC Oxy extended-release tablets. Intellipharmaceutics, of Toronto, was seeking IV abuse-deterrent labeling for its oxycodone hydrochloride tablets intended to manage moderate-to-severe pain when a continuous analgesic is needed for an extended period.